RecruitingNot ApplicableNCT06183541

Effects of Pericapsular Nerve Group Block Applied in Patients Undergoing Hip Fracture Surgery.

Effects of Pericapsular Nerve Group (PENG) Block Applied for Analgesia on the Postoperative Process in Patients Undergoing Hip Fracture Surgery.


Sponsor

Umraniye Education and Research Hospital

Enrollment

70 participants

Start Date

Nov 21, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, it was aimed to compare the multimodal analgesia application or the pericapsular nerve group (PENG) block methods in patients undergoing hip surgery. The effectiveness and benefit rate of the PENG block in postoperative pain will be evaluated. Postoperative pain, need for additional analgesia, range of motion of the hip joint, mobilization time, length of hospital time and adverse events in patients undergoing hip fracture surgery with and without PENG block will be investigated.


Eligibility

Min Age: 30 YearsMax Age: 85 Years

Inclusion Criteria1

  • Patients who will undergo hip fracture surgery Women and men aged 30-85

Exclusion Criteria6

  • Patients under 30 years old, over 85 years old
  • American Society of Anesthesiology (ASA) IV,
  • Those with cognitive impairment (alzheimer, dementia, delirium, etc.)
  • Those with application site infection
  • Those who are allergic to local anesthetic substances
  • Patients are non-consenting patients.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREPericapsular Nerve Group (PENG) Block

Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.


Locations(2)

Umraniye Education and Research Hospital

Istanbul, Umraniye, Turkey (Türkiye)

UmraniyeERH

Istanbul, Umraniye, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06183541


Related Trials